Abatacept retention and clinical response rates were higher in patients who received abatacept earlier (compared with later) in their biologic drug treatment history and in those with RF/ACPA double-positive RA (compared with RF/ACPA double-negative RA). The gene discussed is PRTN3; the disease is rheumatoid arthritis.